NEW YORK (GenomeWeb) – Merit Medical Systems this week agreed to purchase certain assets from Becton Dickinson in connection with BD's proposed acquisition of CR Bard. Merit's proposed asset acquisition is subject to the closing of BD's proposed acquisition of Bard as well as other usual and customary closing conditions. The assets to be acquired are soft tissue core needle biopsy products currently sold by BD under the trade names of Achieve Programmable Automatic Biopsy System, Temno Biopsy System, and Tru-Cut Biopsy Needles.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.